Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5629445 | 0.86 | LMNA (0.56) | APOBEC3AAPOBEC3GLMNASMN1; SMN2HTT | |
| SCHEMBL5628780 | 0.83 | LMNA (0.53) | APOBEC3AAPOBEC3GLMNASMN1; SMN2HTT | |
| SCHEMBL6185623 | 0.83 | HTT (0.51) | NPSR1ALOX5APTP53LMNASMN1; SMN2 | |
| SCHEMBL6185625 | 0.79 | ADRA1D (0.59) | LMNASMN1; SMN2HTTMCHR1TDP1 | |
| SCHEMBL5627256 | 0.78 | SMN1; SMN2 (0.51) | APOBEC3AAPOBEC3GLMNASMN1; SMN2HTT | |
| SCHEMBL6187210 | 0.75 | MAPK1 (0.51) | NPSR1APOBEC3AAPOBEC3GTP53LMNA | |
| SCHEMBL7084322 | 0.73 | MCHR1 (0.49) | TP53LMNASMN1; SMN2HTTMCHR1 | |
| SCHEMBL6186883 | 0.72 | LMNA (0.59) | NPSR1TP53LMNASMN1; SMN2HTT | |
| SCHEMBL7090869 | 0.72 | KDM4E (0.57) | TP53LMNASMN1; SMN2TDP1MEN1 | |
| SCHEMBL5630581 | 0.71 | CYP1A2 (0.51) | NPSR1LMNASMN1; SMN2TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465635-A4 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 2-(4-BENZYL-PIPERAZIN-1-YLMETHYL)- AND 2-(4-BENZYL-DIAZEPAN-1-YLMETHYL)-1H-BENZOIMIDAZOLE ANALOGUES | NEUROGEN CORP (US) | 2005-04-13 | — | — | EP | claimed |
| EP-1465635-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 2-(4-BENZYL-PIPERAZIN-1-YLMETHYL)- AND 2-(4-BENZYL-DIAZEPAN-1-YLMETHYL)-1H-BENZOIMIDAZOLE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-10-13 | — | — | EP | claimed |
| US-20030229074-A1 | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues | NEUROGEN CORPORATION | 2003-12-11 | — | — | US | claimed |
| WO-2003060475-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 2-(4-BENZYL-PIPERAZIN-1-YLMETHYL)- AND 2-(4-BENZYL-DIAZEPAN-1-YLMETHYL)-1H-BENZOIMIDAZOLE ANALOGUES | NEUROGEN CORPORATION (US) | 2003-07-24 | — | — | WO | claimed |
| US-7160879-B2 | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues | NEUROGEN CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160879-B2 | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues | NEUROGEN CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229074-A1 | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues | MCHR1, MCHR2, MC1R | NPSR1 71/4885ALOX5AP 4370/4885APOBEC3A 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.